SUPERNUS PHARMACEUTICALS, INC. Income Taxes Receivable, Current
SUPERNUS PHARMACEUTICALS, INC. (SUPN) had Income Taxes Receivable, Current of $30.80 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Nontrade Receivables, Current
us-gaap:IncomeTaxesReceivable · last filed 2026-08-03
- 2026-06-30: Income Taxes Receivable, Current $30.80M.
- 2025-12-31: Income Taxes Receivable, Current $38.40M.
| Period end | Income Taxes Receivable, Current |
|---|---|
| 2026-06-30 | $30.80M 10-Q · filed 2026-08-03 |
| 2025-12-31 | $38.40M 10-Q · filed 2026-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |